We Investigate the Role of EAAT2 Gene Pathways in Brain Neuroprotection

We are committed to altering the course of neurodegenerative diseases.

  • In 2016, Chairman Vincent Chiang initiated a collaboration with Prof. Ying-Jui Ho from Chung Shan Medical University to develop a novel therapeutic candidate for Parkinson’s disease (PD), Parkinson’s disease dementia (PDD), and dementia with Lewy bodies (DLB). The project aims to address the underlying causes of these neurodegenerative disorders and to develop an innovative treatment capable of modifying disease progression.
  • In 2017, an Investigational New Drug (IND) application was submitted to the U.S. FDA, enabling the launch of a multicenter, double-blind Phase II clinical trial in patients with PDD. The study progressed to the unblinding stage in the second quarter of 2025.

Limitations and Unmet Needs of Current PD Treatments

There remains a strong market demand for a truly revolutionary disease-modifying therapy (DMT).

  • Treatment Limitation: Failure to Modify Disease Progression

    The current standard therapies (such as Levodopa) only alleviate symptoms and do not slow neurodegeneration. There remains a lack of therapies with disease-modifying potential (DMT).

  • Limitations and Complications in Managing Motor Symptoms

    Following long-term Levodopa use, most patients develop dose-related fluctuations, dyskinesias, and waning efficacy within 5 years. Complete elimination of OFF periods, motor fluctuations, and gait/balance abnormalities remains unachievable.

  • Drug Safety and Tolerability Risks

    Long-term Levodopa therapy may lead to toxicity, dyskinesias, and a reduction in drug efficacy over time. Other dopaminergic medications, such as dopamine agonists, also carry risks of side effects (e.g., agitation, hallucinations, sleep disorders).

Clinically validated disease-modifying therapies

BX100 completes global multi-center Phase II trial for PDD.

Key Mechanisms of EAAT2 in Regulating Excitatory Synaptic Stability

Its Critical Role in Neurodegenerative Diseases

  • GLT-1 is the primary glutamate transporter in the central nervous system, responsible for clearing approximately 90% of glutamate from the synaptic cleft. Its dysfunction leading to insufficient glutamate clearance is a key mechanism contributing to neurodegenerative changes.
  • Glutamate is the major excitatory neurotransmitter in the central nervous system. Its excessive accumulation results in glutamate excitotoxicity, which further exacerbates the degeneration of dopaminergic neurons and drives disease progression.
  • EAAT2/GLT-1 serves as a hub for maintaining glutamate homeostasis. Its dysregulation represents a common pathological node in Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and epilepsy, highlighting its potential as a therapeutic target for multiple indications.

Targeting EAAT2 to Re-establish Balance in the Brain

A multi-targeted therapeutic strategy, offering unique benefits beyond current drugs.

BX100 Phase 2 clinical trial is Completed

Multicenter, randomized, double-blind, placebo-controlled trial.

A cross-disciplinary leader deeply embedded in the field of neuroscience

Founder Chiang Wenshun has 30 years of experience in the pharmaceutical industry. His co-technical advisor, Professor He Yingrui (Sun Yat-sen University of Medical Sciences), has 14 years of experience specializing in neurodegeneration research. The team includes experts in clinical, translational medicine, and commercialization.

Key Points:
  • 7 top Taiwanese neurology KOL advisors
  •  

  • Vicent Chiang

    President and CEO

    30+ years of experience in the pharmaceutical and medical aesthetics industry.
    ．BrainX Pharmaceuticals - Founder
    ．RBI Regene Ageing Care Foundation - Founder
    ．Regene Biotech Co., Ltd. - Founder

  •  

  • Andy Huang CFO

    15+ years of experience in Finance & Tax, and Financial Planning for IPOs and TSE/TWSE Listings.

  • Dr. Yvette Huang CTO

    20+ years of experience in drug discovery and development; AI-powered drug design.

  • Dr. Edward Chen

    Director of Medical Research Department

    25+ years experience of pre-clinical and organoid development

  • Zoe Chang, MBA

    Director of Clinical Research Department

    25+ years experience of clinical management

  • Dr. Jimmy Chou

    Medical Research Department

    15+ years experience brain science and in vivo disease model development

  • Dr. Grayson Chen

    Formulation Research Department

    8 years experience in metabolic disease and drug formulation development.

The Dilemma of Current Treatments and Opportunities for Change

Existing levodopa therapy only relieves symptoms, fails to slow disease progression, and is associated with risks such as dyskinesia (45% incidence) and diminishing efficacy. BrainX's DMT therapy directly targets the core mechanisms of neurodegeneration.

References:
  • Long-term levodopa use: 80% of patients experience motor fluctuations within 5 years (J Neurol. 2022).
  • DLB accounts for 6-10% of dementia cases, and no specific treatment exists.
Key Points:
  • Disease-modifying potential
  • Safety advantage (AEs <5% in Phase II trial)

A Revolutionary Breakthrough from Glutamate Toxicity to Neuroprotection

GLT-1 is a core glutamate transporter in the central nervous system. Its dysfunction leads to neuroexcitotoxicity and Lewy body accumulation. BX100 achieves multi-target regulation by upregulating GLT-1 expression.

References:
  • Striatal glutamate concentrations in Parkinson's disease patients increase by 200% (Brain. 2021)
  • Animal models show that GLT-1 activation reduces α-synuclein by 40%
Key Points:
  • Multi-disease application potential (PD/DLB/ALS)
  • Published 3 SCI-indexed papers

A Global Intellectual Property Moat

Core compound, formulation, and use patents are available in the United States (US11234877), the European Union (EP3988267), China (CN1138743), and Japan, with protection until 2040.

References:
  • 12 granted patents (including 5 PCT patents)
Key Points:
  • Patents cover therapeutic and diagnostic uses
  • Freedom to Operate (FTO) analysis completed

A Clear Path from Clinic to Commercialization

Focusing on license-out partnerships and rapid-to-market strategies, leveraging safety data from approved drugs to accelerate indication expansion and mitigate development risk.

Key Points:
  • Target Markets: North America (TAM $13 billion), Asia Pacific (SAM $4.5 billion)
  • IPO Plans Launched in 2026

Contact Us

  • Focused on EAAT2, creating new vitality for neurons.
  • Focused on EAAT2, delivering professional brain health solutions.
  • Regulating GLT-1, Clearing Excitotoxicity, Protecting the Neural Future.
  • Using EAAT2 as the Key to Unlock Brain Metabolic Balance